Two systemic lupus erythematosus (SLE) global disease activity indexes-the SLE Disease Activity Index and the Systemic Lupus Activity Measure-demonstrate different correlations with activation of peripheral blood CD4 + T cells

Human Immunology

Volumn 72, Issue 12, 2011, Pages 1160-1167

  Daca, Agnieszka ^a   Czuszyńska, Zenobia ^a   Smoleńska, aneta ^a   Zdrojewski, Zbigniew ^a   Witkowski, Jacek M ^a   Bryl, Ewa ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Activation markers; CD4 + T cells; Global disease activity; SLAM; SLE disease activity index (SLEDAI)

Indexed keywords

CD69 ANTIGEN; FAS ANTIGEN; GRANZYME B; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PERFORIN;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RATING SCALE; SYSTEMIC LUPUS ACTIVITY MEASURE SCALE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE CCTIVITY INDEX; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, CD; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GRANZYMES; HLA-DR ANTIGENS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PERFORIN; POLAND; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 81955161922     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.08.005     Document Type: Article

References (35)

1. Manson J.J., Isenberg D.A. The pathogenesis of systemic lupus erythematosus. Neth J Med 2003, 61:343-346.
2. Ward M.M., Marx A.S., Barry N.N. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000, 27:664-670.
3. Liang M.H., Fortin P.R., Isenberg D.A., Snaith L. Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int 1991, 11:133-136.
4. Griffiths B., Mosca M., Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005, 19:685-708.
5. Hay E.M. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 1995, 9:437-470.
6. Bae S.C., Koh H.K., Chang D.K., Kim M.H., Park J.K., Kim S.Y. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001, 10:405-409.
7. Hrycek A., Pochopień-Kenig G. [Parameters of disease activity used in systemic lupus erythematosus]. Pol Arch Med Wewn 2004, 111:367-374.
8. Cook H.T., Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006, 2:330-337.
9. Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003, 56:481-490.
10. Via C.S., Handwerger B.S. B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 1993, 5:570-574.
11. Bijl M., Limburg P.C., Kallenberg C.G.M. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001, 60:523-526.
12. Bijl M., Horst P., Limburg P.C., Kallenberg C.G.M. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 2001, 10:866-872.
13. high regulatory T cells indiscriminately kill autologous activated T cells. Immunology 2009, 128(suppl 1):e287-e295.
14. Voskoboinik I., Dunstone M.A., Baran K., Whisstock J.C., Trapani J.A. Perforin: structure, function, and role in human immunopathology. Immunol Rev 2010, 235:35-54.
15. Liu C.C., Walsh C.M., Young J.D. Perforin: structure and function. Immunol Today 1995, 16:194-201.
16. Casciola-Rosen L., Andrade F., Ulanet D., Wong W.B., Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999, 190:815-825.
17. + lupus T cells. J Immunol 2004, 174:3652-3661.
18. + T cells from patients with systemic lupus erythematosus. Rheumatol Int 2010, 30:1627-1633.
19. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
20. Fortin P.R., Abrahamowicz M., Clarke A.E., Neville C., Du Berger R., Fraenkel L., et al. Do lupus disease activity measures detect clinically important change?. J Rheumatol 2000, 27:1421-1428.
21. Corzillius M., Fortin P., Stucki G. Responsiveness and sensitivity to change of SLE disease activity measures. Lupus 1999, 8:655-659.
22. Chang E., Abrahamowicz M., Ferland D., Fortin P.R. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidemiol 2002, 55:488-497. CaNIOS Investigators.
23. Oleinik E.K., Shibaev M.I. Expression of CD95 on peripheral blood lymphocytes in patients with autoimmune diseases and neoplasms. Bull Exp Biol Med 2000, 130:892-894.
24. Crispin J.C., Martínez A., de Pablo P., Velasquillo C., Alcocer-Varela J. Participation of the CD69 antigen in the T-cell activation process of patients with systemic lupus erythematosus. Scand J Immunol 1998, 48:196-200.
25. + lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia. Clin Exp Immunol 2011, 164:17-25.
26. Nakamura S., Sung S.S., Bjorndahl J.M., Fu S.M. Human T cell activation IV. T cell activation and proliferation via the early activation antigen EA1. J Exp Med 1989, 169:677-689.
27. Caruso A., Licenziati S., Corelli M., Canaris A.D., De Francesco M.A., Fiorentini S., et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997, 27:71-76.
28. Biselli R., Matricardi P.M., D'Amelio R., Fattorossi A. Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes. Scand J Immunol 1992, 35:439-447.
29. Han Y., Guo Q., Zhang M., Chen Z., Cao X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009, 182:111-120.
30. Gandhi R., Farez M.F., Wang Y., Kozoriz D., Quintana F.J., Weiner H.L. Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol 2010, 184:4620-4624.
31. Czystowska M., Strauss L., Bergmann C., Szajnik M., Rabinowich H., Whiteside T.L. Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med 2010, 88:577-588.
32. Efimova O.V., Kelley T.W. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway. BMC Immunol 2009, 10:59.
33. Xie D., Hai B., Xie X., Liu L., Ayello J., Ma X., et al. Peripheral CD4+CD8+ cells are the activated T cells expressed granzyme B (GrB), Foxp3, interleukin 17 (IL-17), at higher levels in Th1/Th2 cytokines. Cell Immunol 2009, 259:157-164.
34. Tree T.I., Lawson J., Edwards H., Skowera A., Arif S., Roep B.O., et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 2010, 59:1451-1460.
35. Blanco P., Pitard V., Viallard J.F., Taupin J.L., Pellegrin J.L., Moreau J.F. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:201-211.